Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Benzimidazole Derivatives Act As Dual Urease Inhibitor and Anti-Helicobacter Pylori Agent; Synthesis, Bioactivity, and Molecular Docking Study Publisher



Saeedian Moghadam E1 ; Mohammed Alsadi A2 ; Ghafarzadegan R3 ; Talebi M4 ; Amanlou M4, 5 ; Amini M4, 5 ; Abdeljalil R1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Chemistry, College of Science, Sultan Qaboos University, Muscat, Oman
  2. 2. Department of Crop Sciences, College of Agricultural and Marine Sciences, Sultan Qaboos University, Muscat, Oman
  3. 3. Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran
  4. 4. Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS, Tehran University of Medical Sciences, Tehran, Iran

Source: Synthetic Communications Published:2022


Abstract

A series of benzimidazole derivatives 8a–h were synthesized in acceptable yield and characterized by spectroscopic methods such as 1H-NMR, 13C-NMR, MS, and Elemental analysis. In the urease inhibitory assay, all 8a–h showed higher urease inhibition activity (IC50: 5.85–20.82 µM) in comparison to thiourea and hydroxyurea as standard (IC50: 22 and 100 µM respectively). 8g exhibited the best activity with the IC50 value of 5.85 µM. The docking study represented a possible mode of interaction between 8g and the active site. To investigate the cytotoxicity of the synthesized compounds, an MTT assay was performed on two different cell lines which showed 8a–h have IC50 values higher than 50 µM on both tested cell lines. 8a–h were checked for antibacterial activity and the best activity was found by 8d against Helicobacter pylori with an inhibition zone of 20 mm even stronger than gentamicin with an inhibition zone of 18 mm. © 2022 Taylor & Francis Group, LLC.
Experts (# of related papers)